Haydn T Kissick

List of Publications by Citations

73 papers	3,244 citations	23 h-index	56 g-index
77 ext. papers	4,623 ext. citations	10 avg, IF	5.13 L-index

#	Paper	IF	Citations
73	Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature*, **2016**, 537, 417-421	50.4	834
72	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. *Annual Review of Medicine*, **2018**, 69, 301-318	17.4	265
71	Origin and differentiation of human memory CD8 T cells after vaccination. *Nature*, **2017**, 552, 362-367	50.4	257
70	Effector CD8 T cells dedifferentiate into long-lived memory cells. *Nature*, **2017**, 552, 404-409	50.4	245
69	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. *Nature*, **2019**, 576, 465-470	50.4	237
68	Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. *Nature Immunology*, **2016**, 17, 1226-34	19.1	202
67	Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 9887-92	11.5	166
66	Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1 Stem-like CD8 T Cells during Chronic Infection. *Immunity*, **2019**, 51, 1043-1058.e4	32.3	150
65	Translation is actively regulated during the differentiation of CD8 effector T cells. *Nature Immunology*, **2017**, 18, 1046-1057	19.1	79
64	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. *Cancer*, **2019**, 125, 127-134	6.4	71
63	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. *Clinical Genitourinary Cancer*, **2018**, 16, e563-e575	3.3	52
62	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. *Forum on Immunopathological Diseases and Therapeutics*, **2015**, 6, 7-17		48
61	Defining HPV-specific B cell responses in patients with head and neck cancer. *Nature*, **2021**, 597, 274-278	50.4	48
60	Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis. *Toxicology and Applied Pharmacology*, **2016**, 312, 42-52	4.6	40
59	Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. *Bone*, **2015**, 78, 81-6	4.7	35
58	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. *Clinical Cancer Research*, **2017**, 23, 3823-3833	12.9	30
57	Expression of novel long noncoding RNAs defines virus-specific effector and memory CD8 T cells. *Nature Communications*, **2019**, 10, 196	17.4	28

56	Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer. *Nature*, **2021**, 597, 279-284	50.4	28
55	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. *Current Opinion in Immunology*, **2015**, 35, 15-22	7.8	27
54	Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil. *Cancer Chemotherapy and Pharmacology*, **2010**, 66, 1095-102	3.5	27
53	An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. *Journal of Hematology and Oncology*, **2017**, 10, 107	22.4	26
52	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. *Oncologist*, **2020**, 25, e528-e535	5.7	26
51	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. *Cancer*, **2020**, 126, 575-582	6.4	24
50	Topically applied Melaleuca alternifolia (tea tree) oil causes direct anti-cancer cytotoxicity in subcutaneous tumour bearing mice. *Journal of Dermatological Science*, **2012**, 67, 120-9	4.3	23
49	Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. *Molecular Cancer Research*, **2019**, 17, 2395-2409	6.6	19
48	Extracellular vesicles from bone marrow-derived mesenchymal stromal cells support survival of human antibody secreting cells. *Journal of Extracellular Vesicles*, **2018**, 7, 1463778	16.4	19
47	The scavenger receptor MARCO modulates TLR-induced responses in dendritic cells. *PLoS ONE*, **2014**, 9, e104148	3.7	19
46	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Oncologist*, **2020**, 25, e484-e491	5.7	17
45	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. *OncoImmunology*, **2018**, 7, e1413519	7.2	15
44	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. *Journal of Clinical Pharmacology*, **2018**, 58, 7-24	2.9	15
43	The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 543-555	2.8	14
42	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. *Cancer Medicine*, **2020**, 9, 2752-2760	4.8	12
41	Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. *PLoS ONE*, **2014**, 9, e93231	3.7	11
40	The Role of Regulatory T Cells in Mesothelioma. *Cancer Microenvironment*, **2012**, 5, 165-72	6.1	11
39	Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. *Prostate*, **2015**, 75, 337-47	4.2	9

38	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. *Investigational New Drugs*, **2019**, 37, 1198-1206	4.3	8
37	Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. *Frontiers in Pharmacology*, **2016**, 7, 327	5.6	8
36	Alpha-Tocopheryl succinate: toxicity and lack of anti-tumour activity in immuno-competent mice. *Food and Chemical Toxicology*, **2008**, 46, 508-12	4.7	7
35	Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy. *Advances in Experimental Medicine and Biology*, **2019**, 1210, 121-147	3.6	7
34	T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection. *Journal of Virology*, **2020**, 94,	6.6	7
33	Combined intratumoral regulatory T-cell depletion and transforming growth factor- neutralization induces regression of established AE17 murine mesothelioma tumors. *Journal of Interferon and Cytokine Research*, **2009**, 29, 209-15	3.5	6
32	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. *Clinical Cancer Research*, **2021**, 27, 4836-4847	12.9	6
31	CD45RB Status of CD8 T Cell Memory Defines T Cell Receptor Affinity and Persistence. *Cell Reports*, **2020**, 30, 1282-1291.e5	10.6	5
30	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens as Vaccine Targets for Cancer. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	5
29	Successful combined intratumoral immunotherapy of established murine mesotheliomas requires B-cell involvement. *Journal of Interferon and Cytokine Research*, **2015**, 35, 100-7	3.5	5
28	Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. *Immunology and Cell Biology*, **2012**, 90, 822-6	5	5
27	Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Oncologist*, **2021**, 26, e1742-e1750	5.7	5
26	The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells. *BMC Cancer*, **2015**, 15, 604	4.8	4
25	Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival. *Asian Journal of Urology*, **2016**, 3, 75-81	2.7	4
24	Mechanisms of immune suppression exerted by regulatory T-cells in subcutaneous AE17 murine mesothelioma. *Journal of Interferon and Cytokine Research*, **2010**, 30, 829-34	3.5	4
23	Transcriptional firing represses bactericidal activity in cystic fibrosis airway neutrophils. *Cell Reports Medicine*, **2021**, 2, 100239	18	4
22	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. *Oncologist*, **2021**, 26, 397-405	5.7	4
21	Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. *Frontiers in Oncology*, **2021**, 11, 707050	5.3	3

20	The immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients. *OncoImmunology*, **2020**, 9, 1747731	7.2	3
19	Organized immune cell interactions within tumors sustain a productive T-cell response. *International Immunology*, **2021**, 33, 27-37	4.9	3
18	High Expression of Major Histocompatibility Complex Class I in Clear Cell Renal Cell Carcinoma Is Associated with Improved Prognosis. *Urologia Internationalis*, **2015**, 95, 72-8	1.9	2
17	Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).. *Journal of Clinical Oncology*, **2019**, 37, 473-473	2.2	2
16	Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).. *Journal of Clinical Oncology*, **2019**, 37, e16068-e16068	2.2	1
15	Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).. *Journal of Clinical Oncology*, **2019**, 37, 472-472	2.2	1
14	Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI).. *Journal of Clinical Oncology*, **2020**, 38, 563-563	2.2	1
13	Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).. *Journal of Clinical Oncology*, **2020**, 38, 738-738	2.2	1
12	Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. *Frontiers in Oncology*, **2020**, 10, 622134	5.3	1
11	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. *Oncologist*, **2021**, 26, 1017-1025	5.7	1
10	Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.. *Journal of Clinical Oncology*, **2022**, 40, 340-340	2.2	1
9	Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma.. *Frontiers in Oncology*, **2021**, 11, 793808	5.3	0
8	CMV Status Drives Distinct Trajectories of CD4+ T Cell Differentiation. *Frontiers in Immunology*, **2021**, 12, 620386	8.4	0
7	Considerations for cancer immunotherapy biomarker research during COVID-19. *Endocrine-Related Cancer*, **2020**, 27, C1-C8	5.7	
6	Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).. *Journal of Clinical Oncology*, **2018**, 36, e15022-e15022	2.2	
5	Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).. *Journal of Clinical Oncology*, **2019**, 37, 390-390	2.2	
4	Evaluation of major histocompatibility complex class I expression in clear cell renal cell carcinoma as a prognostic tool.. *Journal of Clinical Oncology*, **2015**, 33, 469-469	2.2	
3	Correlation between inflammatory markers in blood and expression of costimulatory molecules on tumor-infiltrating CD8+ lymphocytes in renal cell carcinoma.. *Journal of Clinical Oncology*, **2017**, 35, 508-508	2.2	

2	Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).. *Journal of Clinical Oncology*, **2021**, 39, e16546-e16546	2.2
1	Reply to Tumor-associated macrophages: "Good cop-bad cop". *Cancer*, **2019**, 125, 1942-1943	6.4